[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100261924":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":19,"centralContacts":23,"locations":33,"responsibleParty":89,"collaborators":10,"id":91,"slug":92,"hasResults":93,"nctId":94,"briefTitle":95,"officialTitle":95,"acronym":10,"eligibilityCriteria":96,"healthyVolunteers":93,"sex":97,"minAge":98,"maxAge":10,"enrollmentInfo":99,"targetDuration":10,"studyType":102,"phases":10,"briefSummary":103,"conditions":104,"keywords":10,"overallStatus":54,"whyStopped":10,"lastUpdateSubmitDate":107,"lastUpdatePostDateStruct":108,"startDateStruct":111,"completionDateStruct":113,"leadSponsor":115,"locationsCount":116},{"fullName":5,"class":6},"Samsung Medical Center","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Small cell lung cancers",null,"To provide molecular characteristics of Small cell lung cancers to proceed SUKSES trial, To assess success rate of molecular profiling of Small cell lung cancers",[13],"Other: No treatment is included in this protocol.",[15],{"type":6,"name":16,"description":17,"armGroupLabels":18,"otherNames":10},"No treatment is included in this protocol.","Tumor tissues (fresh or archival) will be analyzed using NGS-based cancer panel, nanostring CNV, immunohistochemistry and\u002For FISH.\n\nSpecific methods of each molecular tests will be defined with standard laboratory manual developed by pathologists.",[9],[20],{"name":21,"affiliation":5,"role":22},"Se-Hoon Lee, MD, PhD","PRINCIPAL_INVESTIGATOR",[24,29],{"name":25,"role":26,"phone":27,"phoneExt":10,"email":28},"Se-Hoon Lee, MD,Ph.D.","CONTACT","+82-10-4759-7640","sehoon.lee@samsung.com",{"name":30,"role":26,"phone":31,"phoneExt":10,"email":32},"Seoha Kim","+82-2-2148-7668","seoha88.kim@samsung.com",[34,45,53,68,73,81],{"facility":35,"status":36,"city":37,"state":10,"zip":10,"country":38,"countryCode":10,"cosmosGeoPoint":39,"geoPoint":44,"contacts":10},"Gachon University Gil Medical Center","COMPLETED","Incheon","South Korea",{"type":40,"coordinates":41},"Point",[42,43],126.70515,37.45646,{"lat":43,"lon":42},{"facility":46,"status":36,"city":47,"state":10,"zip":10,"country":38,"countryCode":10,"cosmosGeoPoint":48,"geoPoint":52,"contacts":10},"Seoul National University Bundang Hospital","Seongnam",{"type":40,"coordinates":49},[50,51],127.7548,36.4052,{"lat":51,"lon":50},{"facility":5,"status":54,"city":55,"state":10,"zip":56,"country":38,"countryCode":10,"cosmosGeoPoint":57,"geoPoint":61,"contacts":62},"RECRUITING","Seoul","135-710",{"type":40,"coordinates":58},[59,60],126.9784,37.566,{"lat":60,"lon":59},[63,66],{"name":64,"role":26,"phone":65,"phoneExt":10,"email":28},"Se-Hoon Lee, M.D., Ph.D.","82-2-2148-7665",{"name":67,"role":22,"phone":10,"phoneExt":10,"email":10},"Se-Hoon Lee",{"facility":69,"status":36,"city":55,"state":10,"zip":10,"country":38,"countryCode":10,"cosmosGeoPoint":70,"geoPoint":72,"contacts":10},"VHS Medical Center",{"type":40,"coordinates":71},[59,60],{"lat":60,"lon":59},{"facility":74,"status":36,"city":75,"state":10,"zip":10,"country":38,"countryCode":10,"cosmosGeoPoint":76,"geoPoint":80,"contacts":10},"Chungbuk University Hospital","Taebuk",{"type":40,"coordinates":77},[78,79],128.56667,36.26667,{"lat":79,"lon":78},{"facility":82,"status":36,"city":83,"state":10,"zip":10,"country":38,"countryCode":10,"cosmosGeoPoint":84,"geoPoint":88,"contacts":10},"Ulsan University Hospital","Ulsan",{"type":40,"coordinates":85},[86,87],129.31667,35.53722,{"lat":87,"lon":86},{"type":22,"investigatorFullName":67,"investigatorTitle":90,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"MD,PhD","100261924","the-molecular-screening-study-for-the-umbrella-trial-sukses-in-relapsed-small-cell-lung-cancer-patients-sukses-s-100261924",false,"NCT02688894","The Molecular Screening Study for the Umbrella Trial (SUKSES) in Relapsed Small Cell Lung Cancer Patients [SUKSES-S]","Inclusion Criteria:\n\n1. Provision of fully informed consent prior to any study specific procedures.\n2. Patients must be ≥20 years of age.\n3. Histologically or cytologically confirmed Small cell lung cancers\n4. ECOG performance status of 0 to 2\n5. Patients who are being treated or were treated with platinum-based chemotherapy as a first-line treatment\n6. Patients with available archival tissues for molecular analysis or patients who agreed with biopsy for molecular analysis\n\nExclusion Criteria:\n\n1. More than two prior chemotherapy regimen for the treatment of small cell lung cancer\n2. Pregnant or nursing women (women of reproductive potential have to agree to use an effective contraceptive method)\n3. Patients with second primary cancer, except: adequately treated non-melanoma skin cancer, curatively treated in-situ cancer of the cervix, or other solid tumours curatively treated with no evidence of disease for ≤2 years.","ALL","20 Years",{"count":100,"type":101},797,"ESTIMATED","OBSERVATIONAL","This protocol is a molecular screening protocol only. No drug intervention study will be included in this protocol. Based on the molecular profiling, patients may be eligible for drug intervention study of SUKSES trial.\n\nThis procedure can be performed during or after the first-line treatment. DNA will be extracted from the archived or fresh tissue and blood. NGS-based cancer panel and Nanostring CNV will be tested with DNA from tissue and\u002For blood.\n\nImmunohistochemistry and FISH will be done by pathologists using archived or fresh tissue.\n\nTumor tissues (fresh or archival) will be analyzed using NGS-based cancer panel, nanostring CNV, immunohistochemistry and\u002For FISH.\n\nSpecific methods of each molecular tests will be defined with standard laboratory manual developed by pathologists.",[105,106],"Small Cell Lung Cancers","Neuroendocrine Carcinoma","2026-04-23",{"date":109,"type":110},"2026-04-28","ACTUAL",{"date":112,"type":110},"2016-04-29",{"date":114,"type":101},"2028-12",{"name":5,"class":6},6]